For patient

Triple-negative breast cancer (TNBC) is a highly aggressive breast cancer subtype that lacks hormone receptors and the HER2 protein, making it especially challenging to treat and urgently in need of new therapies like antibody-drug conjugates.

What is Triple-Negative Breast Cancer?

Triple-negative breast cancer (TNBC) is a subtype of breast cancer where the cancer cells lack three common receptors known to fuel breast cancer growth: estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2).

TNBC is one of the most aggressive subtypes of breast cancer, characterized by rapid growth, early metastasis, and a poorer overall survival rate. Since it is negative for the common receptors, it does not respond to many standard treatments that target them.

Doctor consulting with patient

Who gets TNBC?

  • •Accounts for 10-15% of all breast cancer diagnoses
  • •Affects younger women (under 40)
  • •More common in Black women or those with BRCA1 mutations

Symptoms of TNBC

  • •A new breast lump or mass
  • •Changes in breast size, shape, feel
  • •Skin changes (puckering, dimpling, thickening, rashes, redness)
  • •Nipple discharge
  • •Changes in nipple position

Overall Survival (OS)

TNBC grows and spreads quickly, often diagnosed at an advanced stage.

According to American Cancer Society data, metastatic (Stage IV) TNBC has a 15% relative survival rate.

Patients with metastatic TNBC (Stage IV) live 11-13 months on average, and TNBC can recur and spread faster than other types, especially in the first 3-5 years after treatment. (National Breast Cancer Foundation)

Breast Cancer Survival Rates

5 Year Relative Survival Rates for Stage IV Breast Cancer, by Subtype

How to read: About 3 out of 20 people diagnosed with triple-negative breast cancer are expected to be alive 5 years later. Relative survival means this cancer survival number takes into account the deaths we'd normally expect in people the same age without cancer.

Triple-negative (HR-/HER2-)

3 out of 20 (14.9%) survive

LOWEST

HR+/HER2- (Hormone Receptor Positive)

7.5 out of 20 (36.5%) survive

HR-/HER2+ (HER2 Positive)

8 out of 20 (40.8%) survive

HR+/HER2+ (Double Positive)

9.5 out of 20 (46.7%) survive

Data represents 5 year relative survival rates for distant/Stage IV breast cancer. Source: SEER Cancer Statistics

Limitations of current therapies

TNBC doesn’t respond to hormone therapy or HER2-targeting drugs. Most triple negative breast cancer treatments still rely on chemotherapy.

Chemotherapy has harsh side effects and doesn't target the biological factors driving TNBC growth. Options like immune checkpoint inhibitors, PARP inhibitors, and antibody-drug conjugates have improved the treatment landscape. However, treatments available today usually keep the disease under control for about 4 to 8 months (Translational Breast Cancer Research). Often, they stop working, and the cancer grows back.

Scientist in laboratory

Why research and innovation matter

TNBC is a form of cancer where traditional therapies simply aren’t effective enough. Antigenix Therapeutics is developing safer, more effective treatments because patients deserve better options

New approaches like ADCs, immunotherapy, nanotechnology, and personalized medicine offer promising hope for TNBC and other high-need cancers, providing the potential for longer, healthier lives.